Phase III trial for postherpetic neuralgia completes enrollment

Journal of Drugs in Dermatology, August, 2007 by Marissa Heller

NeurogesX, Inc recently announced that its phase III clinical trial for NGX-4010 has completed its enrollment. NGX-4010 is a dermal patch that is being evaluated for the treatment of postherpetic neuralgia. NeurogesX has already completed prior phase III trials that have indicated that a single 30- or 60-minute treatment with NGX-4010 applied directly to the site of pain, may provide pain relief for up to 3 months.

The current trial will evaluate the effect of a single 60-minute treatment with the dermal patch or a low-concentration control patch during a 12-week study period.

COPYRIGHT 2007 Journal of Drugs in Dermatology, Inc.
COPYRIGHT 2007 Gale Group

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement

Content provided in partnership with Thompson Gale